Citigroup’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$50.2M Sell
1,899,044
-931,940
-33% -$27.3M 0.02% 643
2025
Q4
$82M Buy
2,830,984
+1,311,982
+86% +$39.4M 0.04% 434
2025
Q3
$42.2M Buy
1,519,002
+848,733
+127% +$21.4M 0.02% 703
2025
Q2
$16.3M Sell
670,269
-1,890,491
-74% -$41.4M 0.01% 1080
2025
Q1
$53.2M Buy
2,560,760
+905,515
+55% +$22.7M 0.03% 536
2024
Q4
$39M Sell
1,655,245
-25,400
-2% -$625K 0.02% 623
2024
Q3
$43M Buy
1,680,645
+849,831
+102% +$21.6M 0.02% 600
2024
Q2
$19.5M Sell
830,814
-77,785
-9% -$1.96M 0.01% 902
2024
Q1
$26.1M Buy
908,599
+246,877
+37% +$7.42M 0.02% 768
2023
Q4
$21.7M Buy
661,722
+14,447
+2% +$393K 0.02% 818
2023
Q3
$18M Sell
647,275
-771,729
-54% -$25.2M 0.01% 816
2023
Q2
$48.4M Buy
1,419,004
+16,147
+1% +$508K 0.03% 451
2023
Q1
$42.2M Buy
1,402,857
+1,092,968
+353% +$33.9M 0.03% 467
2022
Q4
$8.75M Sell
309,889
-99,970
-24% -$3.17M 0.01% 1203
2022
Q3
$13.5M Buy
409,859
+208,067
+103% +$7.64M 0.01% 990
2022
Q2
$6.35M Sell
201,792
-150,110
-43% -$5.25M ﹤0.01% 1389
2022
Q1
$16.2M Sell
351,902
-15,942
-4% -$760K 0.01% 1038
2021
Q4
$22.5M Sell
367,844
-58,093
-14% -$4.02M 0.01% 941
2021
Q3
$31.8M Buy
425,937
+92,448
+28% +$7.76M 0.02% 737
2021
Q2
$30.8M Buy
333,489
+40,489
+14% +$3.44M 0.02% 771
2021
Q1
$26M Buy
293,000
+260,708
+807% +$25.9M 0.02% 808
2020
Q4
$3.01M Buy
32,292
+32,157
+23,820% +$2.56M ﹤0.01% 2478
2020
Q3
$9K Hold
135
﹤0.01% 6669
2020
Q2
$7K Hold
135
﹤0.01% 7166
2020
Q1
$4K Sell
135
-70
-34% -$2.34K ﹤0.01% 7297
2019
Q4
$7K Hold
205
﹤0.01% 7294
2019
Q3
$6K Hold
205
﹤0.01% 7255
2019
Q2
$7K Hold
205
﹤0.01% 7380
2019
Q1
$7K Sell
205
-341
-62% -$10.1K ﹤0.01% 7330
2018
Q4
$13K Buy
546
+135
+33% +$3.8K ﹤0.01% 7053
2018
Q3
$14K Hold
411
﹤0.01% 7231
2018
Q2
$12K Hold
411
﹤0.01% 7111
2018
Q1
$11K Buy
+411
New +$11.1K ﹤0.01% 7003

Other funds holding ARKG

Citigroup's ARKG Position: Q1 2026 in Review

Citigroup reduced its ARK Genomic Revolution ETF (ARKG) stake by 33% in Q1 2026, selling an estimated $27.3M and leaving 1,899,044 shares worth $50.2M. The position accounts for 0.02% of the portfolio, ranked #643.

Citigroup first reported a position in ARKG in Q1 2018 and has held it in 33 quarters since. The position peaked at $82M in Q4 2025. 218 funds tracked by Wall St. Rank hold ARKG as of Q1 2026.

  • Citigroup held 1,899,044 shares of ARK Genomic Revolution ETF worth $50.2M as of Q1 2026.
  • Citigroup sold 931,940 ARK Genomic Revolution ETF shares in Q1 2026, an estimated $27.3M.
  • ARK Genomic Revolution ETF made up 0.02% of Citigroup's portfolio in Q1 2026, its #643 holding.
  • Citigroup first reported a position in ARK Genomic Revolution ETF in Q1 2018 and has held it in 33 quarters since.
  • Citigroup's ARK Genomic Revolution ETF position peaked at $82M in Q4 2025.
  • 218 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.